Pluri Secures China Patent for 3D Cell Expansion, Bolsters Global IP Portfolio
Pluri’s subsidiary secured China patent No. Cn119301238b for its 3D immune cell expansion technology, covering large-scale production of NK cells, TILs and CAR-engineered T cells. This expands its IP portfolio to six markets—U.S., Japan, Korea, Australia, Israel and China—and bolsters licensing and manufacturing partnerships in China’s cell therapy sector.
1. China Patent Grant
Pluri Biotech Ltd. received China patent No. Cn119301238b covering its 3D immune cell expansion technology, enabling large-scale production of NK cells, TILs and CAR-engineered T cells through an automated bioreactor system.
2. Global IP Expansion
The China grant joins existing patents in the U.S., Japan, Korea, Australia and Israel, creating IP coverage across six major pharmaceutical markets and establishing an “IP Bridge” for cross-continental defense of Pluri’s manufacturing methods.
3. Strategic Partnership Potential
The expanded IP portfolio supports Pluri’s strategy to pursue licensing and manufacturing partnerships in China’s growing cell therapy sector by offering scalable, cost-efficient production and reducing partnering risk with robust patent protection.